RNA Q4 2025 Earnings — Avidity Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RNAAvidity Biosciences, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$860,000-71.1% YoY

Gross Profit

-$636,000-74.0% margin

Operating Income

-$254M-29590.5% margin

Net Income

-$237M-27569.9% margin

EPS (Diluted)

$-1.59

QoQ Revenue Growth

-93.1%

Cash Flow

Operating Cash Flow

-$170M

Free Cash Flow

-$175M

Stock-Based Comp.

$43M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$269M

Stockholders' Equity

$1.7B

Cash & Equivalents

$383M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$860,000	$3M	-71.1%
Gross Profit	-$636,000	$3M	-121.4%
Operating Income	-$254M	-$121M	-110.3%
Net Income	-$237M	-$102M	-131.9%

Revenue Segments

Reportable Segment

$860,000100%